Condition
Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung Cancer
Estimated Enrollment: 136
Age Group: 18 Years to 70 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment
Study ID Numbers: 120111|12-C-0111
Study First Received: April 20, 2012
Last Updated: April 20, 2017
Estimated Primary Completion Date: December 31, 2018
Primary Outcome Measures:
Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.|Determine the in vivo survival of CAR gene-engineered cells.
Sponsors and Collaborators:
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Website Link: https://ClinicalTrials.gov/show/NCT01583686
